Nearly one-fifth of patients with non-small cell Lung Cancer (NSCLC) will develop liver metastases (LMs), and the overall treatment strategy of LMs will directly affect the survival of patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results